SEARCH

SEARCH BY CITATION

References

  • 1
    Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol 2010;35:72115.
  • 2
    Burnett JR, Vasikaran SD. Cardiovascular disease and osteoporosis: is there a link between lipids and bone? Ann Clin Biochem 2002;39:20310.
  • 3
    Elbekai RH, El-Kadi AO. Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol Ther 2006;112:56487.
  • 4
    Lee AJ, Kosh JW, Conney AH, Zhu BT. Characterization of the NADPH-dependent metabolism of 17beta-estradiol to multiple metabolites by human liver microsomes and selectively expressed human cytochrome P450 3A4 and 3A5. J Pharmacol Exp Ther 2001;298:42032.
  • 5
    Fujimura T, Takahashi S, Urano T, Kumagai J, Murata T, Takayama K et al. Expression of cytochrome P450 3A4 and its clinical significance in human prostate cancer. Urology 2009;74:3917.
  • 6
    Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 1999;259:2015.
  • 7
    Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:41423.
  • 8
    Ortiz de Montellano PR. The 1994 Bernard B. Brodie Award Lecture. Structure, mechanism, and inhibition of cytochrome P450. Drug Metab Dispos 1995;23:11817.
  • 9
    Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000;10:37388.
  • 10
    Evans WE, McLeod HL. Pharmacogenomics – drug disposition, drug targets, and side effects. N Engl J Med 2003;348:53849.
  • 11
    Du J, Xing Q, Xu L, Xu M, Shu A, Shi Y et al. Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. Pharmacogenomics 2006;7:83141.
  • 12
    Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 2004;23:100.
  • 13
    Du J, Yu L, Wang L, Zhang A, Shu A, Xu L et al. Differences in CYP3A41G genotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese populations. Clin Chim Acta 2007;383:1724.
  • 14
    Qiu XY, Jiao Z, Zhang M, Zhong LJ, Liang HQ, Ma CL et al. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol 2008;64:106984.
  • 15
    Hu YF, Tu JH, Tan ZR, Liu ZQ, Zhou G, He J et al. Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. Xenobiotica 2007;37:31527.
  • 16
    Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 1990;81:16807.
  • 17
    Kalin MF, Zumoff B. Sex hormones and coronary disease: a review of the clinical studies. Steroids 1990;55:33052.
  • 18
    Barrett-Connor E. Clinical review 162: cardiovascular endocrinology 3: an epidemiologist looks at hormones and heart disease in women. J Clin Endocrinol Metab 2003;88:403142.
  • 19
    Rossouw JE. Hormones, genetic factors, and gender differences in cardiovascular disease. Cardiovasc Res 2002;53:5507.
  • 20
    Barrett-Connor E, Bush T. Estrogen and coronary heart disease in women. JAMA 1991;265:18617.
  • 21
    Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. Pharmacogenet Genomics 2007;17:34958.
  • 22
    Han Y, Xu W, Zhang W, Liu N, Ji Y. T-786C polymorphism in the endothelial nitric oxide synthase gene is associated with increased risk of coronary artery disease in a Chinese population. Pharmacology 2010;85:2116.
  • 23
    He MA, Zhang X, Wang J, Cheng L, Zhou L, Zeng H et al. Genetic variation in heat shock protein 60 gene and coronary heart disease in China: tagging-SNP haplotype analysis in a case-control study. Cell Stress Chaperones 2008;13:2318.
  • 24
    Kolovou GD, Anagnostopoulou KK. Apolipoprotein E polymorphism, age and coronary heart disease. Ageing Res Rev 2007;6:94108.
  • 25
    Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007;357:44353.
  • 26
    McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007;316:148891.
  • 27
    Reyes-Hernandez OD, Lares-Asseff I, Sosa-Macias M, Vega L, Albores A, Elizondo G. A comparative study of CYP3A4 polymorphisms in Mexican Amerindian and Mestizo populations. Pharmacology 2008;81:97103.
  • 28
    Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 2001;299:82531.
  • 29
    Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002;12:12132.
  • 30
    Yeh CC, Sung FC, Kuo LT, Hsu WP, Chu HY. Polymorphisms of cytochrome P450 1A1, cigarette smoking and risk of coronary artery disease. Mutat Res 2009;667:7781.
  • 31
    Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Cavallari U, Trabetti E et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006;26:1895900.
  • 32
    Du J, Xu Y, Duan S, Zhang A, Xuan J, Wang L et al. A case-control association study between the CYP3A4 and CYP3A5 genes and schizophrenia in the Chinese Han population. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:12004.
  • 33
    Keshava C, McCanlies EC, Weston A. CYP3A4 polymorphisms – potential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol 2004;160:82541.
  • 34
    Liolitsa D, Powell JF, Prince M, Lovestone S. Association study of the 5-HT (2A) receptor gene polymorphism, T102C and essential hypertension. J Hum Hypertens 2001;15:3359.
  • 35
    Sarmanova J, Benesova K, Gut I, Nedelcheva-Kristensen V, Tynkova L, Soucek P. Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin’s and non-Hodgkin’s lymphomas. Hum Mol Genet 2001;10:126573.
  • 36
    Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997;277:150810.
  • 37
    Muller M, van der Schouw YT, Thijssen JH, Grobbee DE. Endogenous sex hormones and cardiovascular disease in men. J Clin Endocrinol Metab 2003;88:507686.
  • 38
    Arnlov J, Pencina MJ, Amin S, Nam BH, Benjamin EJ, Murabito JM et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med 2006;145:17684.
  • 39
    Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology 2003;144:338298.
  • 40
    Kang YS, Park SY, Yim CH, Kwak HS, Gajendrarao P, Krishnamoorthy N et al. The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clin Pharmacol Ther 2009;85:3128.
  • 41
    Zhang W, Chang YZ, Kan QC, Zhang LR, Li ZS, Lu H et al. CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients. Eur J Clin Pharmacol 2010;66:616.
  • 42
    Gao Y, Zhang LR, Fu Q. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur J Clin Pharmacol 2008;64:87782.